Inflammopharmacology最新文献

{"title":"Role of dexmedetomidine in brain injury: a systematic review.","authors":"Rania Zekry, Rehab H Werida, Ehab S Hegazy, Tarek M Mostafa","doi":"10.1007/s10787-025-01946-0","DOIUrl":"https://doi.org/10.1007/s10787-025-01946-0","url":null,"abstract":"<p><strong>Background: </strong>Brain injuries are major health concern worldwide, that have debilitating effects on patients and affect patients' quality of life; therefore, we are in urgent need of identifying medications that have neuroprotective properties and help to maintain the patients' cognitive function. Dexmedetomidine is a sedative medication commonly used in ICU situations; recent studies show that it may have neuroprotective properties via different mechanisms.</p><p><strong>Aim: </strong>The aim of this article is to review available literature regarding the impact of using dexmedetomidine in various types of brain injury.</p><p><strong>Method: </strong>A systematic review of the published papers on the PubMed and google scholar that investigated the effects of dexmedetomidine on patients with different brain injuries was employed.</p><p><strong>Results: </strong>A total of 17 papers were included in this review, of which 1 was a case report, 6 were animal studies, 1 was a retrospective descriptive study, 2 were retrospective cohorts, 5 were randomized controlled trials, 1 was a scoping review, and 1 was a meta-analysis. These papers demonstrated the effects of dexmedetomidine on patients with traumatic brain injury, intracerebral hemorrhage, ischemic brain injury, status epilepticus, and on patients undergoing craniocerebral surgeries.</p><p><strong>Conclusion: </strong>Dexmedetomidine is a very promising drug to be used in different types of brain injuries and in craniocerebral surgeries because it has demonstrated impressive neuroprotective properties by a variety of mechanisms.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145199249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective.","authors":"Nousheen Khatoon, Anjila Firdous, Meenakshi Hirwani, Ayushmaan Roy, Mohammad Adnan Raza, Ajazuddin","doi":"10.1007/s10787-025-01963-z","DOIUrl":"https://doi.org/10.1007/s10787-025-01963-z","url":null,"abstract":"<p><p>Asthma is a complex and chronic inflammatory condition that continues to pose major challenges in clinical practice due to its varied symptoms and inconsistent responses to standard treatments. In recent years, advances in novel drug delivery systems have opened up new possibilities for emerging more targeted, effective, and patient-compliant therapies. While traditional treatments such as inhaled corticosteroids and long-acting beta agonists remain the backbone of asthma management, their limitations have spurred the development of innovative delivery methods and new therapeutic targets. Biologic therapies, particularly monoclonal antibodies, have emerged as promising options for patients with severe asthma, offering greater precision and fewer systemic side effects. Liposome-based drug delivery, polymer-based drug delivery, dendrimer-based drug delivery, and noisome-based drug delivery have shown significant potential by enhancing drug stability, improving bioavailability, and enabling targeted delivery to the lungs. Additionally, this review article also covers the use of small molecule inhibitors, including those targeting Janus kinase, tyrosine kinase, and phosphodiesterase pathways, which are being explored for difficult-to-treat asthma cases. This review also delves into the latest progress in gene therapy and RNA-based treatments, as well as discusses about clinical trials and their outcomes. These novel approaches highlight a shift towards more personalised and effective asthma care, with the potential to significantly improve patient outcomes.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The neuroinflammatory triumvirate: NF-κB, NLRP3, and mTOR in spinal cord injury.","authors":"Ali Darabniya","doi":"10.1007/s10787-025-01952-2","DOIUrl":"https://doi.org/10.1007/s10787-025-01952-2","url":null,"abstract":"<p><p>After spinal cord injury (SCI), there is a finely choreographed neuroinflammatory response that can profoundly influence secondary injury, neuronal apoptosis, the formation of a glial scar, and long-term functional recovery outcomes. The key multifaceted roles within this neuroinflammatory process are mediated through the NF-κB, NLRP3 inflammasome, and mTOR signaling pathways, which function as interconnected networks controlling cytokine production, the reactivity of astrocytes and microglia, autophagy, and apoptosis. Dysregulation of these pathways leads to increased neuroinflammation and chronic neurological deficits.Emerging preclinical studies demonstrate how targeting single pathways with monotherapy shows modest success; however, with the co-targeting of NF-κB, NLRP3, and mTOR, neuroprotection is achieved through a reduction in inflammatory cascades, stimulation of autophagy, reduction of glial scarring, and ultimately, functional recovery was achieved. New therapeutic strategies, including selective pharmacological inhibitors, multi-gene-based biotechnology, and next-generation biomaterial-assisted therapeutic delivery systems, are emerging and are of interest towards maximizing outcomes while minimizing systemic toxicity. This review details the mechanisms and interactions of NF-κB, NLRP3, and mTOR in SCI, providing a comprehensive overview of upstream regulators, downstream effectors, and feedback loops to regulate cross-talk; emerging multi-target strategies with a view to translational viability and challenges; and the future focus on precision neuroinflammatory modulation. A sophisticated grasp of these interconnected signaling frameworks provides a conceptual framework for next-generation neuroprotective treatments, with the potential to greatly attenuate secondary injury, induce better neural repair, and improve long-term neurological outcomes. Integrative, pathway-targeted approaches have the potential to revolutionize the management of SCI and more effectively expedite the real-world translation of mechanistic-based approaches into clinical interventions.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Mirikizumab in the treatment of moderate to severe inflammatory bowel diseases: a systematic review and updated meta-analysis.","authors":"Joel Gabin Konlack Mekontso, Joseph Yvan Bena Nnang, Samuel G J Fodop, Bishoy I B Elkoumes, Guy Loic Nguefang Tchoukeu, Anifatou B Kortim, Ticha B T Tembi, Akil Olliverre, Jarin Prasa, John Trillo","doi":"10.1007/s10787-025-01971-z","DOIUrl":"https://doi.org/10.1007/s10787-025-01971-z","url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel diseases (IBD) remain challenging to treat despite advances in biologic therapies. Mirikizumab, a selective anti-IL-23p19 monoclonal antibody, shows promise, but its efficacy and safety across IBD populations require a comprehensive evaluation.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing Mirikizumab to placebo in moderate-to-severe IBD. We assessed clinical response, clinical remission, endoscopic remission, adverse events (AEs) and treatment discontinuation. We applied a random-effects model and calculated numbers needed to treat (NNT) and harm (NNH).</p><p><strong>Results: </strong>We included four RCTs (2380 patients). Mirikizumab significantly increased the likelihood of clinical response by 69% (61.0% vs. 36.6%; RR 1.69; 95% CI [1.35, 2.10]; p  <  0.00001; NNT = 4), clinical remission by 74% (37.1% vs. 20.0%; RR 1.74; 95% CI [1.50, 2.02]; p  <  0.00001; NNT = 7), and endoscopic remission by 92% (28.7% vs. 15.4%; RR 1.92; 95% CI [1.63, 2.27]; p  <  0.00001; NNT = 8). This efficacy extended to biologic-failed patients and across both IBD populations. Mirikizumab was safe, with reduced rates of serious AEs (5.2% vs. 9.1%; RR 0.53; 95% CI [0.41, 0.70]; p  <  0.00001; NNH = 24), treatment discontinuation (2.5% vs. 7.5%; RR 0.33; 95% CI [0.20, 0.56]; p  <  0.0001; NNH = 20), and IBD worsening (3.3% vs. 13%; RR 0.26; 95% CI [0.19, 0.36]; p  <  0.00001; NNT = 11).</p><p><strong>Conclusion: </strong>Mirikizumab significantly improves clinical and endoscopic outcomes in moderate-to-severe IBD, with consistent efficacy in biologic-refractory disease and a favorable safety profile, making it a valuable therapeutic option.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic insights into the relationship between anti-inflammatory drug target genes and oral diseases.","authors":"Zelong Hu, Yuchong Xie, Huike Wang, Shouqiang Zhu, Shijia Huang, Minzhe Xin, Haonan Ding, Yuxin Qian, Yingnan Tian, Xuwen Wang, Minxin He, Lei Jin","doi":"10.1007/s10787-025-01959-9","DOIUrl":"https://doi.org/10.1007/s10787-025-01959-9","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) are cornerstones in the management of oral inflammatory pathologies. However, their precise causal effects on a range of oral diseases and the underlying genetic mechanisms remain poorly understood. Concurrently, emerging evidence on the gut-brain axis suggests a potential connection between intestinal inflammation and the pathogenesis of oral diseases. Although preliminary data point to the gut microbiota's role in disease progression, the specific causal pathways and genetic underpinnings remain largely unexplored. Therefore, this investigation was designed to elucidate the potential causal relationships between exposure to anti-inflammatory medications and oral disease risk.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;This study systematically investigates the causal effects of anti-inflammatory medications on oral disease risk through a comprehensive Mendelian randomization (MR) strategy. Our approach integrates a primary two-sample MR using Genome-wide association study (GWAS) summary statistics with a multivariable MR leveraging gene expression quantitative trait locus (eQTL) data to assess specific drug targets from DrugBank. Furthermore, we investigate the gut microbiota as a potential mediator to elucidate the complete mechanistic pathway connecting the drug target to the disease outcome.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Our Mendelian randomization analysis revealed distinct, and often opposing, causal effects of different anti-inflammatory drug classes on oral disease risk. Genetically proxied glucocorticoid use was associated with an increased risk for acute periodontitis (IVW: odds ratio = 1.4786, 95% CI 1.0341-2.114, p = 0.032), Oral and oropharyngeal cancer (IVW: odds ratio = 1.0006, 95% CI 1.00004-1.0011, p = 0.033), and Cellulitis (odds ratio = 1.149, 95% CI 1.0003-1.3199, p = 0.0495). Conversely, paracetamol, a widely used NSAID, demonstrated a protective effect against acute periodontitis (IVW: odds ratio = 0.3338, 95% CI 0.1527-0.7293, p = 0.0059) but was concurrently identified as a risk factor for Oral and oropharyngeal cancer (odds ratio = 1.0016, 95% CI 1.0004-1.0028, p = 0.011), Disease of pulp and periapical tissues (odds ratio = 1.2486, 95% CI 1.0228-1.5242, p = 0.0291), and Dental caries (odds ratio = 1.6037, 95% CI 1.2179-2.1118, p &lt; 0.001). To explore the genetic basis of these associations, we further investigated the role of specific drug target genes. Our findings implicated CASP3 (odds ratio = 1.25004, 95% CI 1.09498-1.42706, p &lt; 0.001) and CCND1 (odds ratio = 1.55479, 95% CI 1.33389-1.81227, p &lt; 0.001) as being significantly associated with the progression of acute periodontitis. In relation to oral and oropharyngeal cancer, significant associations were observed for a suite of genes including HSPA5, TNFAIP6, AKR1C1, CASP1, ANXA1, and MYC. Furthermore, CCND1 also demonstrated a significant association with the progr","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analgesic and anti-inflammatory properties of carbenoxolone: a review.","authors":"Hamid Ahmadpourmir, Hananeh Mohammadi Tabar, Zahra Gholamnezhad, Vahideh Ghorani, Seyedeh Faezeh Taghizadeh, Konstantinos Tsarouhas, Mahmoud Hashemzaei, Ramin Rezaee","doi":"10.1007/s10787-025-01937-1","DOIUrl":"https://doi.org/10.1007/s10787-025-01937-1","url":null,"abstract":"<p><p>Carbenoxolone (CBX) is a glycyrrhetinic acid derivative with potential anti-inflammatory and pain-relieving properties shown by clinical and preclinical studies. In animal studies, CBX reduced pain hypersensitivity by inhibiting gap junction communication, reducing neuroinflammation, and increasing gamma-aminobutyric acid (GABA)-ergic signaling.We reviewed analgesic and anti-inflammatory effects of CBX reported by preclinical (n = 15) and clinical (n = 8) studies following a systematic search in PubMed and Scopus, and discuss its safety profile and kinetic properties. The preclinical studies on rodents employed behavioral pain assessments such as paw withdrawal, head withdrawal, tail flick, licking behavior, and formalin-induced responses, and clinical studies used scoring to record pain severity. Preclinical data indicated the effectiveness of CBX in reducing mechanical, thermal, and chemical hypersensitivity. In clinical studies, topical CBX accelerated lesion healing in herpes-associated pain and oral CBX promoted recovery in peptic ulcers; nevertheless, its role in symptom relief was inconsistent and often secondary to tissue healing. CBX also demonstrated broad anti-inflammatory activities across various models, primarily through the inhibition of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6, suppression of NF-κB and NLRP3 inflammasome signaling, and reduction of oxidative stress markers inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), and nitric oxide (NO). Noteworthy, side effects of CBX include sodium retention, weight gain, electrolyte imbalances, hypokalemia, mild edema, elevated blood pressure, headache, and heartburn. Given the strong preclinical evidence but limited clinical validation, further research is needed to clarify CBX analgesic/anti-inflammatory mechanisms/efficacy and fully elucidate its safety profile.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-10 family cytokines: key regulators and novel therapeutic targets for respiratory diseases.","authors":"Pouya Goleij, Alireza Amini, Sajad Abolfazli, Mohammad Mahdi Heidari, Mohammad Amin Khazeei Tabari, Michael Aschner, Danaé S Larsen, Haroon Khan, Maria Daglia","doi":"10.1007/s10787-025-01975-9","DOIUrl":"https://doi.org/10.1007/s10787-025-01975-9","url":null,"abstract":"<p><p>Respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and infectious conditions including COVID-19 and tuberculosis continue to rank among the foremost causes of illness and death worldwide. Although vaccines, antimicrobial treatments, and anti-inflammatory agents have improved disease management, their overall impact remains limited because of the intricate regulation of immune responses at epithelial surfaces. Within this context, the interleukin-10 (IL-10) cytokine family (comprising IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26) has been identified as a key immunological axis in the respiratory tract. These cytokines possess structural homology and predominantly transmit signals through heterodimeric class II receptors via the JAK-STAT cascade. However, their functions are far from uniform: IL-10 primarily exerts suppressive effects on inflammation, whereas IL-19, IL-20, IL-24, and IL-26 are commonly associated with tissue injury, chronic inflammation, and airway remodeling. IL-22 occupies an intermediate role, promoting epithelial regeneration under certain conditions but aggravating inflammation or tumorigenesis in others. This article reviews recent findings on the IL-10 family in a range of respiratory diseases, emphasizing their context-dependent activity, value as potential biomarkers, and relevance as therapeutic targets. A clearer understanding of how protective versus pathogenic signals are balanced within this cytokine network is essential for designing targeted interventions that preserve host defense while restoring airway integrity.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammopharmacological perspectives on plant-derived compounds: ınteraction with monkeypox virus receptors.","authors":"Faik Gökalp","doi":"10.1007/s10787-025-01960-2","DOIUrl":"https://doi.org/10.1007/s10787-025-01960-2","url":null,"abstract":"<p><p>This study investigates the interaction potential of selected natural compounds derived from medicinal plants with monkeypox virus (MPXV) receptors using molecular docking approaches, with particular emphasis on their possible immunomodulatory and anti-inflammatory relevance. Binding affinities of phytochemicals were compared to the reference compound Cidofovir. Notably, Cucurbitacin I and Cucurbitacin E demonstrated the strongest affinities, surpassing Cidofovir. Among the tested molecules, Cucurbitacin I showed the most favourable interaction profile, followed by Cucurbitacin E, Piperine, Thymol, Carvacrol, and Capsaicin. Detailed molecular interaction analyses revealed key binding residues (ALA2, ALA4, TRP24, ASP32, LEU101, THR133, ASN) within the receptor site. These phytochemicals are well known for their immunomodulatory and anti-inflammatory properties; therefore, their strong interactions with MPXV receptors may highlight a dual therapeutic potential-both in modulating host inflammatory responses and in providing a molecular basis for further exploration of phytochemical-based strategies in inflammation-associated viral pathologies.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the awry Aβ pathway in Alzheimer's disease: hype and hurdles.","authors":"Hayder M Al-Kuraishy, Ghassan M Sulaiman, Ali I Al-Gareeb, Hamdoon A Mohammed, Ali K Albuhadily, Mosleh M Abomughaid","doi":"10.1007/s10787-025-01983-9","DOIUrl":"https://doi.org/10.1007/s10787-025-01983-9","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most common neurodegenerative brain disease due to the progressive accumulation of amyloid protein (Aβ) and neurofibrillary tangles (NFTs). These neuropathological changes trigger excitotoxicity, inflammation, oxidative stress, and neuronal apoptosis. Therefore, targeting Aβ may be operative in the management of AD. However, suppression of normal Aβ, which regulates brain cognitive function, may induce cognitive impairment in healthy individuals. Therefore, this review aims to discuss the potential physiological role of normally present Aβ and neurotoxic Aβ in healthy brains and AD patients, respectively. In addition, in this review, we discussed and explained how targeting neurotoxic Aβ could be effective in the management of AD.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro antioxidant activity and in vivo antinociceptive and anti-inflammatory effects of the hydroethanolic extract from leaves of Myrciaria floribunda (H. West ex Willd.) O. Berg in Swiss mice.","authors":"Izabelly Bianca da Silva Santos, Simone Patricia de Freitas Rosa, Wendel César eSilva Pereira, Bruno Souza Dos Santos, Natanael Teles Ramos de Lima, José Maria Barbosa Filho, Alisson Macário de Oliveira, Thiago Henrique Napoleão, Maria Tereza Dos Santos Correia, Wêndeo Kennedy Costa, Marcia Vanusa da Silva","doi":"10.1007/s10787-025-01972-y","DOIUrl":"https://doi.org/10.1007/s10787-025-01972-y","url":null,"abstract":"<p><p>Myrciaria floribunda (H. West ex Willd.) O. Berg, a native species of the Myrtaceae family, is traditionally used in folk medicine and is known for its anticholinesterase, antioxidant, and antitumor properties. Despite this, its analgesic and anti-inflammatory effects remain underexplored. This study aimed to investigate the in vitro antioxidant and in vivo antinociceptive and anti-inflammatory activities of the hydroethanolic extract from M. floribunda leaves (MfHE). MfHE was prepared and analyzed by HPLC-DAD-MS, revealing 25 compounds, mainly tannins and flavonoids. Quantification showed 403.09 mg GAE/g of total phenolics and 2.94 mg QE/g of flavonoids. Antioxidant potential was evaluated using the DPPH assay (IC₅₀ = 63.24 μg/mL) and total antioxidant capacity (TAC 37.84%). Antinociceptive activity was assessed through acetic acid-induced writhing, formalin, and tail flick tests. MfHE (25, 50, and 100 mg/kg, p.o.) significantly reduced writhes by 35.30%, 47.06%, and 66.47%, respectively, inhibited both phases of the formalin test, and increased latency in the tail flick test by 100% at 100 mg/kg. Anti-inflammatory effects were evaluated in carrageenan-induced paw edema and peritonitis models. MfHE reduced paw edema at all doses and lowered total leukocytes (34.57%, 49.39%, 67.91%), neutrophils (28.31%, 52.84%, 60.33%), and pro-inflammatory cytokines IL-1β (52.46%, 66.84%, 75.85%) and TNF-α (44.75%, 69.05%, 87.26%) in peritonitis test. These findings suggest that MfHE, rich in polyphenols, has promising antioxidant, antinociceptive, and anti-inflammatory properties.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}